This is therefore a comparing of the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation in Global Cord Blood Corporation (NYSE:CO) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood Corporation	N/A	0.00	N/A	0.29	20.87
Zynerba Pharmaceuticals Inc.	N/A	0.00	40.24M	-2.88	0.00

Demonstrates Global Cord Blood Corporation and Zynerba Pharmaceuticals Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows us Global Cord Blood Corporation and Zynerba Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Global Cord Blood Corporation	0.00%	7.6%	4%
Zynerba Pharmaceuticals Inc.	0.00%	-74.8%	-63.3%

Volatility & Risk

Global Cord Blood Corporation is 42.00% less volatile than Standard and Poor’s 500 due to its 0.58 beta. Zynerba Pharmaceuticals Inc. on the other hand, has 4.33 beta which makes it 333.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Global Cord Blood Corporation are 9.3 and 9.3 respectively. Its competitor Zynerba Pharmaceuticals Inc.’s Current Ratio is 8 and its Quick Ratio is 8. Global Cord Blood Corporation can pay off short and long-term obligations better than Zynerba Pharmaceuticals Inc.

Dividends

Global Cord Blood Corporation dividend pay is $0.08 per share with 1.18% dividend yield annually. No dividend is paid out for Zynerba Pharmaceuticals Inc.

Insider and Institutional Ownership

Global Cord Blood Corporation and Zynerba Pharmaceuticals Inc. has shares held by institutional investors as follows: 16.4% and 18.4%. Insiders held roughly 49.6% of Global Cord Blood Corporation’s shares. Competitively, insiders own roughly 3.4% of Zynerba Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Global Cord Blood Corporation	-7.3%	-12.33%	-12.21%	-36.42%	-42.1%	-40%
Zynerba Pharmaceuticals Inc.	-4.15%	-23.26%	-32.85%	-59.08%	-60.78%	-63.1%

For the past year Global Cord Blood Corporation has stronger performance than Zynerba Pharmaceuticals Inc.

Summary

Global Cord Blood Corporation beats on 8 of the 8 factors Zynerba Pharmaceuticals Inc.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.